CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 130 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2020. The put-call ratio across all filers is 0.95 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,949,773 | -16.4% | 361,547 | +3.1% | 0.00% | 0.0% |
| Q2 2023 | $11,900,235 | -4.6% | 350,729 | +1.2% | 0.00% | -25.0% |
| Q1 2023 | $12,475,094 | -19.6% | 346,723 | -0.4% | 0.00% | -20.0% |
| Q4 2022 | $15,521,636 | +63.6% | 348,253 | +3.2% | 0.01% | +66.7% |
| Q3 2022 | $9,488,000 | +6.5% | 337,531 | +2.1% | 0.00% | 0.0% |
| Q2 2022 | $8,912,000 | -22.3% | 330,559 | -1.9% | 0.00% | 0.0% |
| Q1 2022 | $11,472,000 | -9.5% | 336,808 | +2.7% | 0.00% | -25.0% |
| Q4 2021 | $12,678,000 | -27.2% | 328,095 | +1.7% | 0.00% | -33.3% |
| Q3 2021 | $17,410,000 | +433.2% | 322,456 | +230.3% | 0.01% | +500.0% |
| Q2 2021 | $3,265,000 | +992.0% | 97,625 | +572.9% | 0.00% | – |
| Q1 2021 | $299,000 | +17.3% | 14,509 | 0.0% | 0.00% | – |
| Q4 2020 | $255,000 | +3.7% | 14,509 | -12.5% | 0.00% | – |
| Q3 2020 | $246,000 | – | 16,581 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,200,000 | $88,064,000 | 14.40% |
| Octagon Capital Advisors LP | 759,898 | $20,912,393 | 3.21% |
| TSP Capital Management Group, LLC | 251,695 | $6,926,645 | 2.67% |
| 5AM Venture Management, LLC | 310,270 | $8,538,630 | 2.46% |
| COMMODORE CAPITAL LP | 706,665 | $19,447,421 | 2.27% |
| ACUTA CAPITAL PARTNERS, LLC | 122,341 | $3,366,824 | 2.26% |
| Redmile Group, LLC | 1,635,938 | $45,021,014 | 2.14% |
| RTW INVESTMENTS, LP | 3,463,201 | $95,307,292 | 2.01% |
| Eversept Partners, LP | 588,143 | $16,185,695 | 1.37% |
| Affinity Asset Advisors, LLC | 150,000 | $4,128,000 | 1.16% |